{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:28:48Z","timestamp":1780396128726,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s10067-017-3573-1","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T05:21:54Z","timestamp":1487827314000},"page":"1197-1199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barr\u00e9 syndrome after anti-TNF-\u03b1 treatment? Case report and literature review"],"prefix":"10.1007","volume":"36","author":[{"given":"Savvas","family":"Psarelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas P. D.","family":"Hajineocli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Hadjicosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh St. A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1084\/jem.170.5.1627","volume":"170","author":"Y Fong","year":"1989","unstructured":"Fong Y et al (1989) Antibodies to cachectin\/tumor necrosis factor reduce interleukin 1 beta and interleukin 5 appearance during lethal bacteremia. J Exp Med 170:1627","journal-title":"J Exp Med"},{"issue":"1","key":"3573_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2014","unstructured":"Monaco C et al (2014) Anti-TNF therapy: past, present and future. Int Immunol 27(1):55\u201362","journal-title":"Int Immunol"},{"key":"3573_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202715","author":"T D\u00f6rner","year":"2012","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda G et al (2012) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. doi:\n10.1136\/annrheumdis-2012-202715","journal-title":"Ann Rheum Dis"},{"key":"3573_CR4","unstructured":"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&keyword=Enter%20keywords&searchType=name&alreadyLoaded=true&status=Authorised&jsenabled=false&searchGenericType=biosimilars&orderBy=activeSubstance&pageNo=1\n\n. Accessed 8 Sept 2016"},{"issue":"Issue 7","key":"3573_CR5","first-page":"871","volume":"91","author":"W Xu","year":"2013","unstructured":"Xu W, Ma C, Wu J, Zhu J (2013) Journal of. Neurosci Res 91(Issue 7):871\u2013881","journal-title":"Neurosci Res"},{"key":"3573_CR6","unstructured":"Osman T, Yavuz KA et al (2012) Guillain-Barre syndrome developing during infliximab treatment for psoriatic arthritis: a case report. J Clin Anal Med 7(1)"},{"key":"3573_CR7","unstructured":"Aznar J, Porta-Etessam J, Ossorio J, Rosales-Alexander J (2013) Tumor necrosis factor-alpha antagonist and demielynating diseases. J Neurol Neurosci 4(3:2)"},{"key":"3573_CR8","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1212\/NXI.0000000000000205","volume":"3","author":"MJ Bradshaw","year":"2016","unstructured":"Bradshaw MJ, Mobley BC et al (2016) Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol, Neuroinflamm 3:e205. doi:\n10.1212\/NXI.0000000000000205","journal-title":"Neurol Neuroimmunol, Neuroinflamm"},{"key":"3573_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","volume":"13","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA (2014) Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 13:54\u201358","journal-title":"Autoimmun Rev"},{"issue":"5","key":"3573_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/art.21814","volume":"54","author":"I Shin","year":"2006","unstructured":"Shin I, Baer A, Kwon H, Papadopoulos E, Siegel J (2006) Guillain-Barr\u00e9 and miller fisher syndromes occurring with tumor necrosis factor \u03b1 antagonist therapy. Arthritis & Rheumatism. 54(5):1429\u20131434","journal-title":"Arthritis & Rheumatism."},{"key":"3573_CR11","doi-asserted-by":"publisher","unstructured":"Lozeron P, Denier C, Lacroix C, Adams D. (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-\u03b1\u2013blocker therapy. Arch Neurol 66(4)","DOI":"10.1001\/archneurol.2009.11"},{"issue":"5","key":"3573_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G et al (2013) Pattern of demyelination occurring during anti-TNF- therapy: a French national survey. Rheumatology 52(5):868\u2013874","journal-title":"Rheumatology"},{"issue":"12","key":"3573_CR13","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards E, Cupps T, Oliverio P, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis & Rheumatism 44(12):2862\u20132869","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"3573_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jns.12147","volume":"20","author":"P Tsouni","year":"2015","unstructured":"Tsouni P, Bill O, Truffert A, Liaudat C, Ochsner F, Steck A et al (2015) Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst 20(4):397\u2013402","journal-title":"J Peripher Nerv Syst"},{"key":"3573_CR15","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95","journal-title":"Arthritis Res Ther"},{"key":"3573_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","volume":"34","author":"SK Raychaudhuri","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP (2015) Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 34:1019\u20131023. doi:\n10.1007\/s10067-015-2961-7","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3573_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","volume":"64","author":"T Noordenbos","year":"2012","unstructured":"Noordenbos T, Yeremenko N, Gofita I et al (2012) Interleukin-17\u2013positive mast cells contribute to synovial inflammation in Spondylarthritis. ARTHRITIS & RHEUMATISM 64(1):99\u2013109. doi:\n10.1002\/art.33396","journal-title":"ARTHRITIS & RHEUMATISM"},{"key":"3573_CR18","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10067-016-3263-4","volume":"35","author":"SP Raychaudhuri","year":"2016","unstructured":"Raychaudhuri SP, Raychaudhuri SK (2016) IL-23\/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol 35:1437\u20131441","journal-title":"Clin Rheumatol"},{"key":"3573_CR19","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"MD Dominique Baeten","year":"2015","unstructured":"Dominique Baeten MD, Joachim Sieper MD, J\u00fcrgen Braun MD et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534\u20132548. doi:\n10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"key":"3573_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023","author":"J Sieper","year":"2016","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H et al (2016) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. doi:\n10.1136\/annrheumdis-2016-210023","journal-title":"Ann Rheum Dis"},{"key":"3573_CR21","first-page":"39","volume":"9","author":"L Ling","year":"2016","unstructured":"Ling L et al (2016) Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 9:39\u201350","journal-title":"J Inflamm Res"},{"key":"3573_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"LG Sarah","year":"2014","unstructured":"Sarah LG et al (2014) The IL-23- IL-17 immune axis: from mechanism to therapeutic testing. Nat Rev Immunol 14:585\u2013600","journal-title":"Nat Rev Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3573-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T11:40:32Z","timestamp":1492774832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3573-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}